Literature DB >> 9530051

Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images.

N L Kelekis1, R C Semelka, S Worawattanakul, E E de Lange, S M Ascher, I O Ahn, C Reinhold, E M Remer, J J Brown, K G Bis, J T Woosley, D G Mitchell.   

Abstract

OBJECTIVE: The purpose of this study was to define the common appearances of hepatocellular carcinoma (HCC) in patients in North America by analyzing T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images interpreted by radiologists at multiple institutions in North America.
MATERIALS AND METHODS: One hundred thirteen consecutive patients with HCC from eight institutions were included in this retrospective case series. Inclusion criteria included MR imaging examinations performed on 1.5-T MR imagers using T1-weighted breath-hold spoiled gradient-echo images, T2-weighted images, and serial gadolinium-enhanced spoiled gradient-echo images. Diagnosis was established by histology in all patients. Images were analyzed retrospectively for lesion count, lesion diameter as less than or equal to 1.5 cm and greater than 1.5 cm, and signal intensity, by individual experienced radiologists at each institution.
RESULTS: We found 354 HCC lesions in the 113 patients. Tumors were solitary in 63 patients, multifocal in 45 patients, and diffuse in five patients. Lesion appearance on combined T1-weighted, T2-weighted, and immediate gadolinium-enhanced spoiled gradient-echo images was as follows: 102 lesions (29%) were hypointense on T1-weighted images, were hyperintense on T2-weighted images, and exhibited diffuse heterogeneous enhancement; 52 lesions (15%) were isointense on both T1- and T2-weighted images and exhibited diffuse homogeneous enhancement (all of these lesions measured < or = 1.5 cm in diameter); 50 lesions (14%) were hypointense on T1-weighted images, were hyperintense on T2-weighted images, and exhibited diffuse homogeneous enhancement; 33 lesions (9%) were hypointense on T1-weighted images, were hyperintense on T2-weighted images, and exhibited predominantly peripheral rim enhancement; and 27 lesions (8%) were hypointense on T1-weighted images, were isointense on T2-weighted images, and exhibited diffuse homogeneous enhancement. The remaining 90 lesions showed less common patterns. The appearance of HCCs greater than 1.5 cm and of HCCs less than or equal to 1.5 cm was significantly different (p = .001). The appearance of histologically proven HCCs is separately described.
CONCLUSION: The combination of hypointensity on T1-weighted images, hyperintensity on T2-weighted images, and diffuse heterogeneous enhancement was the most common appearance of HCC on MR images in a multiinstitutional patient population in North America. Small HCCs measuring less than or equal to 1.5 cm were frequently isointense on both T1-weighted and T2-weighted images and may be detected on immediate gadolinium-enhanced images only as diffuse homogeneously enhancing lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9530051     DOI: 10.2214/ajr.170.4.9530051

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  19 in total

1.  Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning.

Authors:  Hong Zhao; Jin-Lin Yao; Ying Wang; Kang-Rong Zhou
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

2.  Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma.

Authors:  Vincent Vandecaveye; Frederik De Keyzer; Chris Verslype; Katya Op de Beeck; Mina Komuta; Baki Topal; Ilse Roebben; Didier Bielen; Tania Roskams; Frederik Nevens; Steven Dymarkowski
Journal:  Eur Radiol       Date:  2009-05-14       Impact factor: 5.315

3.  Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI.

Authors:  H Rhee; M-J Kim; M-S Park; K A Kim
Journal:  Br J Radiol       Date:  2012-05-02       Impact factor: 3.039

Review 4.  Magnetic resonance imaging of the cirrhotic liver: An update.

Authors:  Agnes Watanabe; Miguel Ramalho; Mamdoh AlObaidy; Hye Jin Kim; Fernanda G Velloni; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

6.  Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis.

Authors:  Shotaro Enomoto; Hideyuki Tamai; Naoki Shingaki; Yoshiyuki Mori; Kosaku Moribata; Tatsuya Shiraki; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Journal:  Hepatol Int       Date:  2011-01-09       Impact factor: 6.047

7.  Role of Diffusion Weighted Imaging (DWI) for Hepatocellular Carcinoma (HCC) Detection and its Grading on 3T MRI: A Prospective Study.

Authors:  Shiva Shankar; Naveen Kalra; Anmol Bhatia; Radhika Srinivasan; Paramjeet Singh; Radha K Dhiman; Niranjan Khandelwal; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2016-09-01

Review 8.  Hepatobiliary MR imaging with gadolinium-based contrast agents.

Authors:  Alex Frydrychowicz; Meghan G Lubner; Jeffrey J Brown; Elmar M Merkle; Scott K Nagle; Neil M Rofsky; Scott B Reeder
Journal:  J Magn Reson Imaging       Date:  2012-03       Impact factor: 4.813

Review 9.  MRI of hepatocellular carcinoma: an update of current practices.

Authors:  Hina Arif-Tiwari; Bobby Kalb; Surya Chundru; Puneet Sharma; James Costello; Rainner W Guessner; Diego R Martin
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

10.  VIP inhibits human HepG2 cell proliferation in vitro.

Authors:  Afaf Absood; Bin Hu; Nermine Bassily; Lisa Colletti
Journal:  Regul Pept       Date:  2007-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.